HOME >> BIOLOGY >> NEWS
Jefferson scientists find gene expression pattern may predict behavior of leukemia

The expression pattern of certain genes may someday help doctors to diagnose and predict whether or not an individual has an aggressive form of B-cell chronic lymphocytic leukemia (CLL), Jefferson cancer researchers have found.

Scientists, led by Carlo Croce, M.D., director of Jefferson's Kimmel Cancer Center and professor and chair of microbiology and immunology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, looked at the expression of genes that encoded microRNAs (miRNAs), tiny pieces of genetic material that are thought to be important in the regulation of gene expression and in the development of cancer. MiRNAs can serve as stop signs for gene expression and protein synthesis, and are thought to play important roles in regulating gene expression in development.

Reporting in both the online and the August 10 print version of the Proceedings of the National Academy of Sciences, the researchers taking advantage of a microarray chip Dr. Croce and his colleagues designed that carries all the known human miRNA genes compared the expression of miRNA genes in human CLL samples with that of normal white blood cells, or lymphocytes, called CD5+ B cells. CLL, the most common adult leukemia in the Western world, is characterized by an abnormal increase in the number of B cells.

"We found two specific genetic signatures," Dr. Croce says. One expression pattern of miRNA genes in CLL correlated with a deletion of a chromosomal region called 13q14. This region contained two small miRNA genes that are turned off in about 60 percent of CLL cases. The deletions at 13q14 represent an indicator of a good prognosis for the disease, he notes.

The other miRNA signature was associated with mutations in the Ig or immunoglobulin gene, which also indicates a good prognosis, says Dr. Croce. The researchers also found that the expression of one of the miRNA genes, miR-16, was reduced in both signatures.

"This suggests that CLL
'"/>


10-Aug-2004


Page: 1 2

Related biology news :

1. Jefferson Lab detector technology aids development of cystic fibrosis therapy
2. Jefferson researchers develop microchip to track genetic signature of cancer and normal tissue
3. Jefferson scientists use gene therapy to restore function of damaged heart cells in lab
4. Jefferson researchers uncover biochemical clues to how cells migrate in embryos
5. Jefferson and Brigham and Womens researchers find blue light important for setting biological clock
6. Jefferson Lab experiment generates THz radiation 20,000 times brighter than anyone else
7. Jefferson scientists show neural stem cells can become dopamine-making brain cells in laboratory
8. Jefferson scientists show how collagen gene mutation leads to osteoarthritis
9. Jefferson scientists use gene repair technique to change albino mice hairs to black
10. Jefferson scientists show drug is effective against a Hepatitis C Virus model in the laboratory
11. Jefferson scientists propose mechanism to control the bodys red blood cell and platelet production

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/2/2019)... ... November 01, 2019 , ... Stay on top of current ... device industries. Access to all webinars is free, so be sure to register today ... , Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , ...
(Date:10/30/2019)... Va. (PRWEB) , ... October 30, 2019 , ... ... offering from the Farm Credit Knowledge Center in which participants will learn about ... industry best practice relating to these technologies. , Participants will have the ...
(Date:10/30/2019)... ... October 30, 2019 , ... Amberdata Inc., the ... firms, including Fenbushi Capital, DF Capital, Rising Tide Fund, and HWVP. The ... to further accelerate its position as the leading data provider of institutional-grade blockchain ...
Breaking Biology News(10 mins):
(Date:10/22/2019)... , ... October 22, 2019 , ... ... has announced that its lead program, DBI-001, met its primary safety endpoints, with ... labeled phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s ...
(Date:10/17/2019)... ... October 16, 2019 , ... ... easy-to-understand, web-based genetic counseling information, has published a new white paper that explores ... and provides guidance as to how patients and medical providers can be kept ...
(Date:10/10/2019)... Md. (PRWEB) , ... October 09, 2019 , ... ... announced Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote ... 27–30 October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist ...
(Date:10/10/2019)... (PRWEB) , ... October 10, 2019 , ... R3 Stem ... The next course is October 18-19th, 2019 in Las Vegas with spots still open. ... He completed training at several Ivy League universities including Cornell, Harvard and Dartmouth. He ...
Breaking Biology Technology:
Cached News: